Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (331)	4/20/1998 1:54:00 AM
From: John Dwyer	Read Replies (2) \| Respond to of 1494

This is all true, and I am also impressed that he pulled this off with NTII so close to bankruptcy. Still, there is the Phase IIb trial before the Phase III study and $2 million is barely enough to cover that trial. Plus they are still doing the Xerecept trial, right? They spent $1.2 million last quarter... even if they manage to reduce that to $1 million, this deal only gives them 2 quarters. The original Phase II for memantine took 8 months to complete. I can't see how they are going to make it without more money. John, perhaps you can help me understand this deal. I read this as Children's Hospital giving up the rights for AIDS dementia in exchange for a cash infusion for NTII and a piece of the AIDS dementia pie that belongs to Merz. This could be a large revenue stream but it will come later, once Merz's Phase III's are completed. I don't see Merz paying for NTII's Phase III for neuropathic pain... is this right? The license to NTII from Children's was for dementia _and_ neuropathic pain... now that license belongs to Merz. Exactly how much has NTII given up here? Can NTII initiate another partnership for the Phase III trials? I don't mean to be a bear here... I actually own a substantial chunk of NTII stock. I'm just trying to get a feeling for how much this deal is really going to help NTII. John